Form 4: Accuray Director Granted 56,603 Restricted Stock Units

Accuray Inc. Director Joseph E. Whitters received a grant of 56,603 Restricted Stock Units, vesting fully in November 2026.

Summary

• Director Joseph E. Whitters of Accuray Inc. (ARAY) was granted 56,603 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Accuray's common stock.
• The RSUs were granted on November 28, 2025, and are scheduled to vest 100% on November 13, 2026.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine insider equity grant, which aligns director interests with shareholders, but does not provide new operational or financial performance information about the company.

Positives

• The grant of Restricted Stock Units to a director aligns the director's long-term interests with those of shareholders, as the value is tied to future stock performance.
• The use of a Rule 10b5-1(c) plan for the transaction indicates a pre-scheduled arrangement, which is a best practice for insider trading compliance.

Risks

• The ultimate value realized from the Restricted Stock Units is contingent on the future market price of Accuray Inc.'s common stock, which could decline.

Future Outlook

The filing does not provide a general future outlook for the company. However, the vesting schedule for the RSUs indicates a future milestone for the director's equity compensation.

Industry Context

The grant of Restricted Stock Units is a common form of equity compensation for directors and executives across various industries, including medical technology. This practice is standard for aligning the interests of company leadership with long-term shareholder value.

Comparison to Industry Standards

• RSU grants are a standard component of director compensation packages in the medical device and healthcare technology sectors, comparable to practices at companies such as Varian Medical Systems (now Siemens Healthineers), Elekta, or Intuitive Surgical.
• The specific number of units granted would typically be evaluated in the context of the director's overall compensation, company size, and peer group benchmarks to assess its competitiveness and appropriateness within the industry.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Director Joseph E. Whitters constitutes a related party transaction, which is a standard compensation event disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's long-term financial interests with the company's stock performance, potentially encouraging decisions that benefit shareholder value. Minor potential for future dilution upon vesting.
• Employees: No direct impact on employees is mentioned in this filing.

Next Steps

• The 56,603 Restricted Stock Units will vest on November 13, 2026, at which point the director will receive shares of common stock.

Key Dates

Recommendation

This filing is a routine Form 4 reporting an equity grant to an existing director. It provides no new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The grant itself is a standard compensation practice designed to align director incentives with shareholder interests, which is generally a neutral to slightly positive governance signal. Therefore, an investor would likely maintain their current position based solely on this filing.

Keywords

Accuray Inc., ARAY, Restricted Stock Units, RSU, Insider Transaction, Form 4, Director Compensation, Equity Grant, Joseph Whitters